Meta Platforms
META
Alphabet-C
GOOG
Alphabet-A
GOOGL
Vale SA
VALE
Coinbase
COIN
US Stock MarketDetailed Quotes
AGIO Agios Pharmaceuticals
- 34.460
- -0.920-2.60%
Close Jan 24 16:00 ET
- 34.460
- 0.0000.00%
Post 20:01 ET
1.97BMarket Cap2.96P/E (TTM)
35.840High34.110Low522.47KVolume35.360Open35.380Pre Close18.13MTurnover1.03%Turnover RatioLossP/E (Static)57.03MShares62.58052wk High1.21P/B1.74BFloat Cap22.23052wk Low--Dividend TTM50.52MShs Float138.850Historical High--Div YieldTTM4.89%Amplitude15.770Historical Low34.703Avg Price1Lot Size
About Agios Pharmaceuticals Company
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
Company Profile
SymbolAGIO
Company NameAgios Pharmaceuticals
Listing DateJul 24, 2013
Issue Price18.00
Founded2007
CEOMr. Brian Goff
MarketNASDAQ
Employees386
Fiscal Year Ends12-31
Address88 Sidney Street
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02139-4169
Phone1-617-649-8600
Websitehttp://www.agios.com
Company Executives
- Name
- Position
- Salary
- Brian Goff
- Chief Executive Officer and Director
- 3.42M
- Tsveta Milanova
- Chief Commercial Officer
- 3.73M
- Dr. Sarah Gheuens, M.D.,PhD
- Chief Medical Officer and Head of Research and Development
- 2.87M
- James William Burns
- Chief Legal Officer
- 1.93M
- Cecilia Jones
- Chief Financial Officer
- 1.21M
- T. J. Washburn
- Principal Accounting Officer, Vice President and Controller
- --
- Dr. Jacqualyn A. Fouse, PhD
- Chairman of the Board
- 447.25K
- Kaye Foster
- Lead Independent Director
- 440.95K
- Jeffrey D. Capello
- Independent Director
- 663.68K
- Dr. Maykin Ho, PhD
- Independent Director
- 424.75K
- Dr. Rahul D. Ballal, PhD
- Independent Director
- 427.25K
- Catherine Owen
- Independent Director
- 659.94K
- Dr. David P. Schenkein, M.D.
- Independent Director
- 417.25K
- Dr. David T. Scadden, M.D.
- Independent Director
- 429.75K
- Cynthia Smith
- Independent Director
- 419.91K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.